<DOC>
	<DOCNO>NCT01604408</DOCNO>
	<brief_summary>LY2495655 investigational drug test muscle waste . Muscle waste include shrink muscle weakness . This occur muscle longer active usual . When muscle longer use , become weaker .</brief_summary>
	<brief_title>A Study Older Participants Who Have Fallen Have Muscle Weakness</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Paresis</mesh_term>
	<criteria>Sustained least 1 fall within 1 calendar year study screening . Requires ≥12 second perform repeat chair stand test unable complete test screening . Hand grip strength ≤37 kilogram ( kg ) men ( 81.4 pound ) ≤21 kg woman ( 46.2 pound ) screen . Can stand chair walk ≥10 meter without human assistance ( gait aid acceptable cane [ ] , crutch , walker ) screening . Able climb least 1 step staircase without human assistance accord participant screening ( use handrail allow ) . Have screen clinical laboratory test result within normal reference range population , result acceptable deviation judge clinically significant investigator . Major low limb pain neurologic impairment vestibular vertigo visual impairment could severely confound measure physical performance . Recent low limb fracture and/or major low limb surgery . Planned major surgical procedure within 6 month follow study drug dosing . Have low extremity amputation foot , leg , and/or thigh . Have body mass index ( BMI ) ≥35 kg/m2 . Severe vitamin D deficiency . Underlying muscle disease ageassociated muscle waste disuse atrophy . Current use previous use drug know influence muscle mass performance . Have recent neurologic injury ( &lt; 6 month study drug dose ) stroke spinal cord injury . History malignant neoplasm 18 month first study drug dosing . Have history presence unstable cardiovascular pulmonary comorbidities . Have positive fecal occult blood ( FOB ) test screen participant provide stool sample FOB test first study drug dose . Have either severe ongoing liver disease aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 time upper limit normal ( ULN ) , alkaline phosphatase ( ALP ) &gt; 1.5 time ULN , total bilirubin &gt; 1.5 time ULN screening . Have estimate creatinine clearance &lt; 20 mL/minute . Have history severe allergic reaction monoclonal antibody . Are males female partner childbearing potential agree use contraception treatment period study 15 week last dose investigational product ( study drug ) . Have know allergy LY2495655 , constituent , related compound . Have severe active psychiatric disease cognitive impairment MiniMental State Examination ( [ MMSE ] &lt; 24 ) make participant unlikely understand inform consent form comply protocol procedure . Excessive consumption alcohol abuse drug . Have uncontrolled diabetes mellitus . Have ocular trauma , ophthalmologic surgery , eye laser treatment within 6 month study drug dose . Have hyponatremia ( serum sodium level &lt; 135 millimoles/Liter ( mmol/L ) screen unless retest show normonatremia study drug dosing .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>